Enlarge
|
RICHS CETYL MYRISTOLEATE CMO PLUS CAPSULES. A considerable investment into your joint account. 100 Gelatine Caps.
Price Now: £39.99
Product Code: 1939
|
Cetyl Myristoleate CMO is one of the latest discoveries in nutritional research for arthritis relief.
Mice never develop arthritis. That's because they produce Cetyl Myristoleate CMO naturally which prevents them from ever developing the disease.
Over the decade both osteoarthritis and rheumatoid arthritis sufferers who have taken Cetyl Myristoleate CMO have gained relief from their symptoms, reporting a dramatic improvement with decreased stiffness and pain, increased flexibility and range of motion and reduced swelling and redness.
Extra Discounts when you buy more than one of any product.
Buy any 2 products and save 2.5%
Buy any 3 to 5 products and save 5%
Buy any 6 to 10 products and save 7.5%
Buy any 11 to 20 products and save 10%
Buy any 21 to 50 products and save 12.5%
Description
Arthritis is a complex disease thought to affect one in five of the population and is generally accepted to be the leading cause of movement limitation and disability.
Now there is a relatively new discovery of a natural substance, Cetyl Myristoleate CMO, which shows great promise of making a great contribution in non-infective types of arthritis.
Cetyl Myristoleate CMO was discovered and isolated by one person, working alone, on a quest to find a cure for arthritis. Harry W. Diehl, while employed by the National Institute of Arthritis, Metabolism, and Digestive Diseases, specialised in sugar chemistry.
He used his chemical knowledge and research instincts to great advantage, identifying and characterising over 500 compounds, several of which were patented by the National Institutes of Health (NIH). His most significant discovery before Cetyl Myristoleate CMO was a method of synthesizing 2-deoxydextroribose, a sugar used in the preparation of oral polio vaccine by Dr. Jonas Salk.
Diehl's interest in discovering a way to help victims of arthritis began over 40 years ago, when his friend and next door neighbour, a carpenter, developed severe rheumatoid arthritis. His condition deteriorated over time until he became disabled. The neighbour had a family to support, but his arthritis made that impossible. Diehl is a deeply religious man whose feelings overwhelmed him as his friend's condition worsened. Harry thought, "Here I am working at the National Institutes of Health, and I have never seen anything that was good for curing arthritis." He decided to establish a laboratory in his home and embark on a search for something to relieve the pain and disability of his neighbour and the millions of people who suffer from arthritis. Unfortunately, he was too late to help the neighbour, but Diehl's research did lead to the discovery of Cetyl Myristoleate CMO.
As a researcher, Diehl knew that finding a cure for arthritis first meant inducing the disease experimentally in research animals. He started with mice, and quickly realised that he was unable to induce arthritis in them. Diehl said he tried every way he could to give those mice arthritis, but they just would not get it. Then, he contacted a researcher in California who wrote to him, "If you or anyone else can give mice arthritis, I want to know about it, because mice are 100% immune to arthritis." At that moment, Diehl's research instincts told him that what he wanted was already somewhere in those mice.
It was a long, tedious job, working on his own in his spare time, but Diehl finally found the factor Cetyl Myristoleate CMO - that protected mice from arthritis. As Diehl said, "It didn't come on a silver platter to me, but after years of chemical sleuthing and just old-fashioned chemical cooking, I found it!"
On thin layer chromatography of methylene chloride extract from macerated mice, Diehl noticed a mysterious compound, which was subsequently identified as Cetyl Myristoleate CMO. As Diehl was to prove, Cetyl Myristoleate CMO circulates in the blood of mice and makes them immune to arthritis.
Cetyl Myristoleate CMO is now known to exist in sperm whale oil and in a small gland in the male beaver. At this time no other sources in nature are known to contain Cetyl Myristoleate CMO. While the first amounts of Cetyl Myristoleate CMO for experimentation were extracted from mice, Diehl quickly developed a method for making Cetyl Myristoleate CMO in the lab by the esterification of myristoleic acid.
Cetyl Myristoleate, an oil, is the hexadecyl ester of the unsaturated fatty acid cis-9-tetradecenoic acid. The common name for the acid is myristoleic acid. Myristoleic acid is found commonly in fish oils, whale oils, dairy butter, and kombo butter. The chemical formula for Cetyl Myristoleate is (Z)-ROCO(CH2)7CH=CH(CH2)3CH3.
Cetyl Myristoleate CMO was unrecorded in chemical literature until Diehl's discovery was reported. The current Merck Index of Chemicals does not list Cetyl Myristoleate CMO. A search of Chemical Abstracts lists Diehl's method of extracting Cetyl Myristoleate from mice, but contains no reference to Cetyl Myristoleate CMO prior to his 1977 patent.
To test his theory that mice are immune to arthritis because of Cetyl Myristoleate CMO, Diehl began to experiment on laboratory rats. This research was reported in an article written in conjunction with one of his colleagues at NIH in the Journal of Pharmaceutical Sciences.
In summary, this paper reports that ten normal mice were injected in the tail with Freund's Adjuvant (heat-killed desiccated Mycobacterium butyricum) to which rats and certain other rodents are susceptible. In a period of 10-20 days, no noticeable swelling developed in the legs or paws. Mice in a second group were injected in the left hind paw. Again, after 10-20 days, no swelling was detected as determined by comparison of the measurements of paws at the time of injection.
Then, a group of rats was injected with Cetyl Myristoleate CMO, and 48 hours later, they were given the arthritis-inducing Freund's adjuvant. A control group of rats was given Freund's adjuvant only. Both groups of rats were observed for a total of 58 days with respect to weight change, hind and front leg swelling, and general well-being. All rats receiving only Freund's adjuvant developed severe swelling of the front and hind legs, lagged in weight gain, and were lethargic and morbid. Those receiving Cetyl Myristoleate CMO before receiving Freund's adjuvant grew an average of 5.7 times as much as the control group and had little if any evidence of swelling or other symptoms of polyarthritis.
The authors concluded that it was apparent that Cetyl Myristoleate CMO gave virtually complete protection against adjuvant-induced arthritis in rats. Furthermore, a 1:1 mixture of Cetyl Myristoleate CMO and a homologue, cetyl oleate, gave results not significantly different from administering Cetyl Myristoleate CMO alone.
Diehl patented his discovery in 1977, receiving a use patent for rheumatoid arthritis. He then sought pharmaceutical companies to conduct human trials with Cetyl Myristoleate CMO, but none were interested in his discovery. Perhaps the lack of interest was because Cetyl Myristoleate CMO was a natural substance and could not be granted a product patent, or maybe because drug companies know they will have to run through 25,000 to 35,000 substances before they find one that makes it to market. Diehl had made a major nutritional discovery, and no one was interested! Being a scientist, not a marketing expert, Diehl let his discovery lay dormant for about 15 years.
As Diehl got older, he began to experience some osteoarthritis in his hands, his knees, and his heels. His family physician tried the usual regimen of cortisone and non-steroidal anti-inflammatory drugs without much effect on the course of the disease. Finally his physician told Harry he could not have any more cortisone. So, Diehl said, "I thought about my discovery, and I decided to make a batch and use it on myself." He did, and successfully cured himself of his osteoarthritis.
Many of his family members and friends became aware of the relief Diehl got from his discovery, and they wanted to try it too. Time after time, people with both rheumatoid and osteoarthritis received astounding relief with Cetyl Myristoleate CMO. Before long, family members and friends grew into customers, and Cetyl Myristoleate CMO appeared on the market as a dietary supplement in 1991.
In common with many other natural substances and drugs, the exact mechanism of Cetyl Myristoleate CMO physiologic activity is unclear. As a fatty acid ester, it appears to have the same characteristics as the essential fatty acids, linoleic and alpha linolenic acids, except stronger and longer lasting. These fatty acids are referred to as "essential fatty acids" because the human body cannot make them and we must ingest them in our diets. These EFA's truly are essential to normal cell structure and body function and function as components of nerve cells, cell membranes, and hormone-like substances known as prostaglandins. Many of the beneficial effects of a diet rich in plant foods is a result of the low levels of saturated fat and the relatively higher levels of EFA's. While a diet high in saturated fat has been linked to many chronic diseases, a diet low in saturated fat, but high in EFA's prevents these very same diseases. The use of EFA's over an extended period of time has been shown to decrease the pain, inflammation, and limitation of motion of arthritis.
The difference between the activity of EFA's and Cetyl Myristoleate CMO is that the quantity required and the period of time over which EFA's are taken are markedly longer.
While EFA's must be taken over extended periods, sometimes many years, and intake varies widely from hundreds to thousands of grams. Cetyl Myristoleate CMO seems to have properties in common with EFA's, but it acts faster and lasts longer.
Because EFA's are necessary for normal functioning of all tissue, it is not surprising that the list of symptoms of EFA deficiency is a long one. In chronic inflammatory processes, the supply of EFA's is depleted. Cetyl Myristoleate CMO appears to have the ability to correct the imbalance created by chronic inflammation. Like EFA's, Cetyl Myristoleate CMO turns off the fires of chronic inflammation by serving as a mediator of prostaglandin formation and metabolism.
The effects of Cetyl Myristoleate CMO can be further enhanced by combining it with other natural substances such as omega-3 fish or flaxseed oil. Vitamin E, Glucosamine Sulphate and MSM and Lipase.
|
Would you like to send this to a friend?
|
Short basket
Your basket is empty
Currency selector
Subscribe
Register for our email updates...
|
Home Page
Add to Favourites
Secure Online Payments 
Delivery Worldwide 
0800 038 0303
